00
Yuhan Corp
000100.KS·KRXSeoul KRFounded 19265,000 employees
Mid CappharmaPublicMetabolicOncology
Platform: Obesity/Onc
Market Cap
$6B
All Drugs
4
Clinical Trials
5
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (000100.KS)
Loading 000100.KS stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pemiratamab | 000-5882 | Phase 2 | 1 | ALK | MigraineProstate Ca | ||
| Mirinaritide | 000-4574 | Phase 2/3 | 2 | Cl18.2 | ADHDMCC | ||
| 000-7991 | 000-7991 | Phase 1 | 1 | FXIa | RCCGA | ||
| Zenoglumide | 000-8811 | Phase 2 | 1 | USP1 | RCCLN |
SEC Filings & Financial Documents
SEC filings are not available for KRX-listed companies.
Yuhan Corp trades on KRX (KR). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (5)